It has been suggested that SPARC exerts the tumor suppressor effects in ovarian cancer through inhibition of cEBPβ, NFkB, AP-1, and their downstream inflammatory effects (John et al., 2019). Here, NFKB1 is linked to ovarian carcinoma.